Apollo Hospitals Q4 FY25: 60% PAT Growth & Outlook

Apollo Hospitals Enterprise Limited, one of Asia’s premier healthcare service providers and India’s first corporate hospital chain, has once again demonstrated robust financial performance. On May 30, 2025, the company released its Q4 FY25 results, showing a 60.41% year-on-year growth in profit after tax (PAT). This notable increase reflects not only operational excellence but also the resilience and scalability of Apollo’s healthcare model in a challenging economic and healthcare environment.

This article dives into the full-year and quarterly financial performance of Apollo Hospitals for FY25, analyzes key figures, share price movements, analyst ratings, and the company’s growth prospects across its healthcare verticals.

📊 Apollo Hospitals Q4 FY25: Financial Performance Highlights

➤ Profit After Tax (PAT)

In Q4 FY25, Apollo reported a PAT of ₹414 crore, an impressive 60.41% YoY growth compared to ₹258 crore in Q4 FY24. This growth mirrors the continued strength in core hospital operations, along with cost management and improved occupancy rates.

➤ Revenue from Operations

Revenue for the January–March 2025 quarter stood at ₹5,592 crore, up 13.11% from ₹4,943 crore in the same period last year. This growth was driven by higher footfalls, expansion of new hospital units, and a growing contribution from diagnostics, pharmacy, and Apollo’s digital health platform.

➤ EBITDA and Margins

The consolidated EBITDA for Q4 FY25 was ₹769.7 crore, with EBITDA margins at 13.67%. This is an encouraging sign of better efficiency and optimized resource utilization across units.

➤ Earnings Per Share (EPS)

Apollo Hospitals posted basic and diluted EPS of ₹27.10 for Q4 FY25, compared to ₹17.65 in Q4 FY24. The annual EPS for FY25 reached ₹100.56.

📅 Apollo Hospitals FY25 (Full-Year) Financial Overview

These numbers underscore the company’s excellent full-year performance with double-digit growth across key indicators.

💰 Dividend Announcement

Apollo Hospitals has recommended a final dividend of ₹10 per share for FY25, rewarding long-term shareholders and reflecting strong free cash flow generation. This dividend aligns with the company’s capital allocation policy to return value to investors while reinvesting in expansion.

📈 Share Price Performance and Market Sentiment

On June 2, 2025, following the results announcement, Apollo Hospitals shares opened with a 0.92% gain at ₹6,944 but soon corrected, closing around ₹6,894 per share. The stock saw an intraday high of ₹7,090 and a low of ₹6,906.

This volatility reflects profit-booking by investors and mixed sentiment despite strong quarterly numbers. However, analysts remain optimistic about medium- to long-term prospects.

🏦 Share Price Target and Analyst Ratings

🔹 Citi

• Rating: Buy

• Target Price: ₹8,260

• View: Citi maintained its positive stance, citing consistent EBITDA and revenue growth at 20% and 13% respectively. The broker believes Apollo’s operational leverage and growing 24/7 platform will continue to drive profitability.

🔹 Goldman Sachs

• Rating: Buy

• Target Price: ₹7,850

• View: While the Q4 results were marginally below Goldman’s expectations, they remain bullish due to Apollo’s planned addition of 3,500 beds, Keimed integration, and the scaling of the digital health platform.

Both brokerages consider Apollo a key beneficiary of India’s rising healthcare demand, increased insurance penetration, and public-private partnership initiatives.

🏥 Business Model: A Diversified Healthcare Giant

Apollo Hospitals operates across several verticals, creating a diversified revenue model that reduces cyclicality and enhances scalability.

1. Hospitals & Clinics

• 71 hospitals with over 12,000 beds (expanding further)

• Specialties: Cardiology, Oncology, Neurology, Orthopedics, Transplants, etc.

2. Apollo Pharmacy

• One of India’s largest pharmacy chains with 5,000+ outlets

• Contribution to stable recurring income

3. Apollo 24/7 Digital Platform

• Online doctor consultations, diagnostics, wellness plans

• Rapid growth during and post-pandemic, now becoming a key business line

4. Diagnostics and Preventive Healthcare

• Diagnostics contribute significantly to patient acquisition

• Preventive healthcare and wellness camps for long-term retention

5. Apollo Health Insurance, Education & Global Projects

• Emerging verticals contributing to strategic expansion

• Medical colleges, nursing schools, international consultancy

🚀 Growth Drivers for the Future

Apollo is strategically aligned with key macro trends in the healthcare space. Some major tailwinds include:

✅ Expansion of Bed Capacity

• Addition of 3,500 new beds over the next few years

• Focus on Tier-2 and Tier-3 cities to capture untapped demand

✅ Digital Transformation

• Scaling Apollo 24/7 platform for nationwide healthcare delivery

• Increased revenue share from digital consultations and diagnostics

✅ Integration of Keimed

• Efficient backend integration to improve inventory and supply chain for pharmacy operations

✅ Medical Tourism

• Strong global brand with patients from Middle East, Africa, and Asia

• Specialized high-end treatment centers attract international clientele

✅ Strategic Partnerships

• Collaborations with state governments, insurance firms, and technology partners for healthcare innovations

⚠️ Risks and Challenges

While Apollo’s trajectory is upward, there are certain risks investors should consider:

• Regulatory Risks: Changes in pricing norms or government interventions could impact profitability

• Talent Shortage: Quality medical professionals are in short supply, impacting scalability

• Digital Health Competition: Intense competition from startups and aggregators in the digital space

• Capital-Intensive Nature: High capital expenditure could put pressure on short-term returns

• Forex Exposure: Earnings from international patients subject to currency fluctuations

📚 FAQs: Apollo Hospitals Q4 FY25

🔸 What is Apollo Hospitals’ PAT for Q4 FY25?

Apollo reported a net profit of ₹414 crore, marking a 60.41% YoY increase over ₹258 crore in Q4 FY24.

🔸 What was the revenue growth in Q4 FY25?

Revenue from operations increased by 13.11% to ₹5,592 crore in Q4 FY25 from ₹4,943 crore in Q4 FY24.

🔸 What dividend has Apollo Hospitals announced?

The board has recommended a final dividend of ₹10 per share for FY25.

🔸 What are analyst share price targets for Apollo Hospitals?

• Citi: ₹8,260

• Goldman Sachs: ₹7,850

🔸 What is the business model of Apollo Hospitals?

Apollo operates hospitals, pharmacies, diagnostics labs, digital health services, and medical education, offering an end-to-end healthcare ecosystem.

🔚 Conclusion

Apollo Hospitals continues to impress with consistent growth, digital transformation, and strategic investments. Its Q4 FY25 results reflect strong operational and financial performance, backed by robust revenue growth and healthy margins.

Investors tracking healthcare stocks may consider Apollo as a long-term bet, especially given its strong management, expanding digital ecosystem, and rising healthcare demand in India.

However, prudent analysis of market conditions, regulatory factors, and personal investment goals is essential before making decisions.

ALSO READ: Nielsoft IPO 2025: Full Analysis & Investment Guide